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Abstract
Background
The intravenous anesthetic propofol acts as a positive allosteric modulator of glycine (GlyRs) and γ-aminobutyric
acid type A (GABAARs) receptors. Although the role of transmembrane residues is recognized, little is known
about the involvement of other regions in the modulatory effects of propofol. Therefore, the influence of the
large intracellular loop in propofol sensitivity of both receptors was explored.

Methods

The large intracellular loop of α1 GlyRs and α1β2 GABAARs was screened using alanine replacement. Sensitivity
to propofol was studied using patch-clamp recording in HEK293 cells transiently transfected with wild type or
mutant receptors.

Results

Alanine mutation of a conserved phenylalanine residue within the α1 large intracellular loop significantly
reduced propofol enhancement in both GlyRs (360 ± 30 vs. 75 ± 10%, mean ± SEM) and GABAARs (361 ± 49% vs.
80 ± 23%). Remarkably, propofol-hyposensitive mutant receptors retained their sensitivity to other allosteric
modulators such as alcohols, etomidate, trichloroethanol, and isoflurane. At the single-channel level, the ability
of propofol to increase open probability was significantly reduced in both α1 GlyR (189 ± 36 vs. 22 ± 13%) and
α1β2 GABAAR (279 ± 29 vs. 29 ± 11%) mutant receptors.

Conclusion

In this study, it is demonstrated that the large intracellular loop of both GlyR and GABAAR has a conserved single
phenylalanine residue (F380 and F385, respectively) that influences its sensitivity to propofol. Results suggest a
new role of the large intracellular loop in the allosteric modulation of two members of the Cys-loop superfamily.
Thus, these data provide new insights into the molecular framework behind the modulation of inhibitory ion
channels by propofol.

Topics:
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What We Already Know about This Topic
•

Propofol positively modulates receptors for the inhibitory transmitters γ-aminobutyric acid type A
(GABA) and glycine, but the molecular mechanisms involved are unclear

What This Article Tells Us That Is New
•

A single homologous residue in the large M3-M4 intracellular loops of the α1subunits of GABAAand
glycine receptors modulates the action of propofol but not of other general anesthetics

GLYCINE and γ-aminobutyric acid receptors (GlyRs and GABAARs) mediate fast synaptic inhibition in the central
nervous system.1,2 These receptors are members of the Cys-loop receptor family, which share considerable
structural and functional features.3,4 As pentamers, they assemble around a central pore that transiently opens,
allowing the passive diffusion of anions.3,4 Similar to other members of the family, their topology consists of an
extracellular N -terminal domain, containing the binding site for the agonist, four transmembrane domains
(TM1-TM4) of which TM2 is critical for pore formation, and a large intracellular loop connecting TM3 and TM4.

To date, molecular cloning has identified 5 subunits of the GlyR (α1–4 and β) and 19 subunits of the GABAAR,
with the GlyR α1β and GABAAR α1β2γ2combinations being predominant in the adult mammalian central nervous
system.1,2
GABAAR and GlyR play important roles in the actions of general anesthetics, including propofol,5,–,9 which is
widely used in intensive care units.10 Previous studies indicated that these receptors contain sites important for
propofol action.6,11,12 For instance, residues in the TM domains in α1and β2/3subunits of the GABAAR were shown
to be important for actions of anesthetics, including propofol.13,–,21 Experiments using a photoreactive analog of
etomidate identified two residues (α1M236 in M1 and β2M286 in M3) as part of a binding pocket for this
anesthetic.22 In addition, based on the capacity of propofol to protect a sulfhydryl-specific reagent from reacting
with a substituted cysteine, it was proposed that M286 in M3 served as an anesthetic binding site in β2.23 A more
recent study showed that binding of the photoreactive analog of etomidate to this site was either directly or
allosterically inhibited by other general anesthetics, suggesting complex intramolecular interactions.24 In
addition to binding sites in TM2/TM3of α/β subunits in GABAAR, a tyrosine in TM4 (Y444) was found to influence
the action of propofol, but not etomidate, on the receptor.14
Studies in animal and molecular experimental models have shown that the sites of general anesthetics on
GABAAR and GlyR are somewhat overlapping for different chemical structures. For example, transgenic mice
carrying propofol-insensitive GABAARs (β3N26 5M) also showed resistance to etomidate and exhibited
substantial reductions in the modulatory actions of the volatile anesthetic enflurane.19 Similarly, it was reported
that residues S267 and A288 of α1GlyRs,25 which previously had been reported as critical for modulation by
alcohols and enflurane,26 also affected propofol sensitivity.
Although these previous studies have predicted that several residues might constitute a propofol binding
pocket, the absence of high-resolution structures of drug-receptor complexes for eukaryotic receptors has
hindered a complete understanding of the molecular mechanisms underlying propofol actions. Molecular
analysis based on homology modeling approaches showed that the implicated TM domain residues form a
water-filled cavity that might be able to accommodate structurally unrelated molecules.16,27 However, the
structure and characteristics of these putative cavities remain unresolved.18,19,22,–,24 For example, in cysteine
cross-linking studies, propofol weakly protected the M286 residue but was not able to protect the β2N265C
residue from modification by p -chloromercuribenzene sulfonate, implying that this residue does not contribute
significantly to the binding site.23 Moreover, the replacement of α1N265 or β2M286 with bulky hydrophobic
residues promoted changes in channel gating and increased agonist potency, complicating the interpretation
regarding the reduced propofol sensitivity.13,28
All these studies are in agreement with the idea that residues in the TM domains are important for propofol
actions in both GABAAR and GlyRs. However, little is known about the contribution of other receptor regions. In
this regard, a recent study has demonstrated that the large intracellular loop (LIL) of the α1GlyR can influence
the allosteric effects exerted by ethanol,29,30 which has been proposed to act at a site in the TM domains.
Therefore, in the current study we investigated the influence of the LIL on the allosteric action of propofol in two
members of the Cys-loop superfamily. Our results identified a single phenylalanine residue, conserved in the
α1subunit of both GABAARs and GlyRs, which affects their sensitivity to propofol. These results provide novel
information about the relevance of the LIL in the allosteric modulation of the Cys-loop superfamily.

Materials and Methods
Complementary DNA Constructs.

Mutations were inserted using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) in
constructs encoding the human GlyR α1subunit subcloned in the pCI vector (Promega, Madison, WI) and the rat

α1and β2GABAAR subunits subcloned in the pRK5 vector (Clontech, Mountain View, CA). All mutations were
confirmed by full sequencing. The GlyRs and GABAAR amino acids were numbered according to their position in
the mature protein sequence.

Cell Culture and Transfection.

HEK293 cells (CRL-1573; American Type Culture Collection, Manassas, VA) were cultured using standard
methods. For the GlyR experiments, HEK293 cells were cotransfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) with the α1GlyR plus the pGreenLantern plasmid (Invitrogen) codifying the green fluorescent
protein (ratio 1:1; 2 μg DNA for each plasmid). Expression of green fluorescent protein was used as a marker of
positively transfected HEK293 cells and recordings were made after 18–36 h. In some experiments in which
GABAAR α1β2γ2subunits were expressed, HEK293 cells were cotransfected using Lipofectamine 2000 (Invitrogen)
with the α1and β2subunits subcloned in the pRK5 vector and the γ2subunit subcloned in the vector internal
ribosome entry site 2-enhanced green fluorescent protein (pIRES2-EGFP, Clontech) using a cotransfection ratio
for α1β2γ2of 1:2:5. To express the α1β2subunit combination, cells were cotransfected with the α1subunit
subcloned in pRK5 and the β2subunit subcloned in the pIRES2-EGFP, using the 1:2 ratio, respectively.

Electrophysiology.

Whole cell recordings were performed as previously described.29,30 A holding potential of −60 mV was used.
Patch electrodes were filled with (in mM): 140 CsCl, 10 2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid,
10 HEPES (pH 7.4), 4 MgCl2, 2 adenosine-5′-triphosphate and 0.5 guanosine-5′-triphosphate. The external
solution contained (in mM): 150 NaCl, 5 KCl, 2.0 CaCl2, 1.0 MgCl2, 10 HEPES (pH 7.4), and 10 glucose. The
amplitude of the γ-aminobutyric acid (GABA) or glycine current was assayed using a brief (1–2 s) pulse of GABA
or glycine every 60 s. The modulation of the GABA or glycine current by propofol (2,6 diisopropylphenol; Sigma–
Aldrich, St Louis, MO) was assayed using a pulse of glycine (EC10) or GABA (EC10) coapplied with propofol for each
receptor studied, without any preapplication. The EC10and EC50values were obtained from concentrationresponse curves for GABA (1–1000 μM) and glycine (1–100 μM), and the response was normalized to saturating
concentrations of the agonist (100%). In all the experiments, a brief pulse of 1 mM GABA or glycine was
performed at the end of the recording period to verify that the concentration used corresponded to the actual
EC10in each cell. Cells that displayed responses < EC5or > EC15were discarded. The methodology for singlechannel recordings in the outside-out configuration has been previously published.30,31 Briefly, patch pipettes
were coated with R6101 elastomer (Dow-Corning, Midland, MI) and had tip resistances of 7–15 megaohms after
fire polishing. Cells were voltage clamped at −60 mV for GlyRs and −100 mV for GABAARs and the data were
filtered (5 kHz low-pass 8-pole Bessel) and acquired at 50 kHz using pClamp software (Molecular Devices,
Sunnyvale, CA). Etomidate, ethanol, butanol, and trichloroethanol were purchased from Sigma–Aldrich.
Isoflurane was purchased from Baxter (Baxter International Inc., Deerfield, IL). Agonist and allosteric drug
solutions were applied to cells using a stepper motor-driven rapid solution exchanger (Warner Instrument Corp.,
Hamden, CT). Cells were maintained in extracellular medium containing (in mM): 150 NaCl, 5 KCl, 2 CaCl2, 10
HEPES, 10 glucose; pH 7.4. The intracellular recording solution contained (in mM): 140 CsCl, 2 MgATP, 10 2bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid and 10 HEPES; pH 7.2.

Data Analysis.

Whole cell data analysis was performed using OriginPro 7.0 (OriginLab, Northampton, MA). Nonlinear regression
analysis was used to fit concentration-response curves for glycine or GABA responses. Determination of
significant differences between control and drug treatment groups were performed using one-way ANOVA or
paired Student t tests followed by the Bonferroni correction post hoc test. Concentration-response curves were
generated by fitting the data to the Hill equation: I = Imax /(1 + EC50/[A]n), where I is the current, Imax is the
maximum current, [A] is the agonist concentration, and n is the Hill coefficient. All results are expressed as

mean ± SEM; values of P < 0.05 were considered statistically significant. Data from single-channel recordings
were idealized using the segmentation K-means algorithm in the QUB software suite (The Research Foundation
State University of New York, Buffalo, NY). Dwell time histograms were fitted with three or four exponential
components using Clampfit software (Molecular Devices), and mean open times were obtained from the
proportionally weighted averages of the individual components. Values for open probability were calculated
from idealized records. All-points amplitude histograms were generated and fitted with Gaussian functions using
ClampFit.

Results
A Conserved Phenylalanine Residue is Important for the Sensitivity of GlyRs and GABAAR
to Propofol

We tested the propofol sensitivity in a series of truncated GlyRs in which a large extension of the LIL was
deleted. Three truncated forms of the GlyR, referred to in this study as Δ326–384, Δ326–355, and Δ355–384,
were constructed and examined (fig. 1A). When the major portion of the LIL was deleted in Δ326–384, the
potentiation of the glycine-activated current by propofol (30 μM) was significantly reduced from 363 ± 33% to
70 ± 12% (fig. 1, B andC). In contrast, the sensitivity of the ▵326–355 mutant (358 ± 48%) was similar to wild
type (tested at EC10). Sensitivity of the ▵355–384 mutant to propofol was attenuated to 71 ± 13% (fig. 1C),
which is consistent with the view that propofol effects on GlyRs are influenced by residues located in the Cterminal region. In order to identify critical amino acids involved in propofol modulation within the G326-Q384
sequence, a sequential series of substitutions of the wild type amino acids with alanine and concentrationresponse curves for potentiation of the glycine current by propofol (1–100 μM) were constructed. These
analyses showed that with the exception of the mutant 376MRKLF380→376AAAAA380(376–380A), all the other
mutants retained their normal sensitivity to propofol (fig. 2A). For example, the sensitivity to 30 μM propofol
was reduced to 65 ± 14% in the 376–380A mutant (open circles , n = 18) compared with 360 ± 30% in wild type
(closed circles , n = 22). Additional single alanine substitutions showed that only the replacement of the
phenylalanine residue (F380A) was able to affect the propofol modulation of GlyRs (75 ± 10%, fig. 2, B and C).

Fig. 1. Deletion of the segment between residues E326 and A384 in the large intracellular loop (LIL) of the
α1glycine receptor (GlyRs) reduced its sensitivity to propofol. (A) Schematic representation of the GlyR subunit
topology. The entire sequence of the LIL for human α1 GlyRs is shown. Three functional mutants were generated
for α1GlyR by deletion of different regions of the LIL. The arrows indicate the deleted segments and truncated
sequences are illustrated by the dashed line. The numbers indicate the positions in the mature polypeptide. (B)

Glycine-activated (EC10) current in wild type GlyRs was enhanced by propofol (PRO, 30 μM). In contrast, the
sensitivity to propofol was significantly reduced in the Δ326–384 and Δ355–384 truncated GlyRs, whereas the
sensitivity of the Δ326–355 mutant did not change. (C) The graph shows that the sensitivity to propofol was
significantly reduced when the segment Δ355–384 was deleted (one-way ANOVA with Bonferonni correction
post test). The bars represent the mean ± SEM. *** Significance of P < 0.001.

Fig. 2. Replacement of the F380 residue by alanine in the large intracellular loop (LIL) of α1GlyRs reduced the
sensitivity to propofol. (A) Graph summarizes the percentage of potentiation in the wild type (black circles) and
several alanine-scanning substitution mutants between residues G355 and R392. Five residues were replaced
systematically in each mutant. The 376–380A mutant (white circles) was less sensitive to propofol. (B) Glycineevoked currents were enhanced by propofol (PRO) in the wild type receptor only, whereas the F380A mutant
was less sensitive. (C) The plot summarizes the sensitivity to propofol (30 μM) in the wild type and five mutant
GlyR α1subunits between residues M376 and F380. The bars represent the mean ± SEM. *** Significance of P <
0.001.
Given the functional and structural homology of the GABAARs with the GlyRs,1,2 we hypothesized that the action
of propofol on the GABAAR could similarly be influenced by residues located within the LIL. Because residues of
both α and β subunits have been implicated in the sensitivity of GABAARs to propofol,17 we deleted a
homologous intracellular sequence near the TM4 domain in both the α1and β2subunits (fig. 3A). The γ2subunit,
however, does not appear to be required for the potentiation of GABA-evoked currents by propofol.32 To further
confirm these results, we tested the sensitivity of GABAAR α1β2γ2and α1β2combinations and did not find any
significant differences (345% potentiation for α1β2γ2and 340% potentiation for α1β2). Based on these data, we
used GABAARs composed of α1β2subunits in our subsequent experiments. Deletion of the sequence between
positions R354 and S388 in the α1subunit (α1Δ354–388β2) significantly reduced the potentiation of GABAAR by
propofol (74 ± 18%, n = 14) (fig. 3, B and C). However, when the homologous deletion in the β2subunit was
examined, the sensitivity to propofol was unaltered (361 ± 49%, n = 8) (fig. 3C). Therefore, we carried out
alanine scanning of the C-terminal region of the LIL of the α1subunit. We found that propofol produced
equivalent modulation of all mutants, with the exception of 384TFNSV388→384AAAAA388(384–388A), which was
potentiated by only 98 ± 23% (fig. 4A, open circles). Consequently, we next determined which amino acids in this

region were involved. Similar to the α1GlyR, there is a conserved phenylalanine residue (F385) in the
homologous position in the α1GABAAR, which when mutated caused a significant reduction in propofol
potentiation (80 ± 23%) (fig. 4, B and C). In contrast, mutations at flanking residues had no effect on the
potentiation by propofol (fig. 4C). Thus, these data allow us to conclude that a conserved phenylalanine residue,
in both the GlyR and GABAAR α1subunits, is critically important for the allosteric modulation exerted by propofol.

Fig. 3. Deletion of a region of the large intracellular loop (LIL) in the γ-aminobutyric acid type A receptor
(GABAAR) α1subunit reduced its sensitivity to propofol. (A) Schematic representation of the GABAAR subunit.
Functional GABAAR mutants were generated by deletion of homologous regions of the α1and β2subunits. (B)
GABA-activated currents in wild type receptors are consistently potentiated by propofol (PRO). In contrast,
propofol effects in α1Δ354–388 were significantly attenuated, whereas the sensitivity of β2Δ346–422 mutant
was similar to that of the wild type receptor. (C) The graph summarizes the percentage of potentiation in the
wild type and truncated forms of the GABAARs by propofol. The bars represent the mean ± SEM. *** Significance
of P < 0.001.

Fig. 4. A conserved phenylalanine residue in γ-aminobutyric acid type A receptor (GABAAR) α1subunit is
important for sensitivity to propofol. (A) Graph summarizes the percentage of potentiation in the wild type
(black circles) and several alanine-scanning substitution mutants between residues R354 and V388. Five residues
were replaced systematically each time. Only the 384–388A mutant (white circles) was significantly less sensitive
to propofol. (B) GABA-evoked currents were enhanced by propofol (PRO) in the wild type (WT) receptor, but not
in the F385A mutant. (C) The graph summarizes the sensitivity to propofol (30 μM) in the wild type and five
mutant GABAAR α1subunits between T384 and V388. The F385A mutant was less sensitive to propofol. The bars
represent the mean ± SEM. *** Significance of P < 0.001.

Replacement of a Phenylalanine Residue Within the LIL Selectively Reduced the
Sensitivity to Propofol but Not to Other Allosteric Modulators

Suggested putative sites of propofol action in the TM domains in both GlyRs and GABAARs were often associated
with the effects of other structurally unrelated molecules. These observations suggest that these sites might be
related to more than one allosteric modulator. To address this issue, we tested the sensitivity of the propofolresistant mutants that we identified to alcohols, neurosteroids and other intravenous or volatile anesthetics.
Contrary to the idea that there is a common molecular site for pharmacological modulators,16,–,19,26,33,34 our
electrophysiological data show that the sensitivity of the mutant receptors to modulation by other allosteric
regulators was unaffected (fig. 5A, B). For instance, the volatile anesthetic isoflurane potentiated both the GlyR
WT (183 ± 19%, n = 8) and the F380A mutant (186 ± 18%, n = 8) to a similar degree (fig. 5A). Notably, GABAevoked currents in the GABAAα1F385Aβ2propofol-hyposensitive receptor were potentiated by the intravenous
anesthetic etomidate (265 ± 32%), which has been suggested to share a common or overlapping binding site22,23

(fig. 5C). Likewise, isoflurane was able to potentiate both wild type and F385A mutant receptors in a similar
manner (fig. 5D). Altogether, contrary to the previously reported molecular site for propofol,16,–,18,33,34 our data
suggest that mutation of a conserved phenylalanine residue within the LIL affects only the sensitivity to
propofol, but does not alter the sensitivity to other allosteric modulators.

Fig. 5. Propofol-hyposensitive receptors retain normal sensitivity to other positive allosteric modulators. (A)
Glycine-evoked currents were enhanced by ethanol (ETOH, 100 mM) and isoflurane (ISO, 500 μM) in the F380A
mutant. (B) Potentiation of the glycine-evoked current in wild type and F380A GlyRs by positive allosteric
modulators. (C) γ-aminobutyric acid-evoked currents were enhanced by etomidate (ETO, 5 μM) and isoflurane
(ISO, 500 μM) in the F385A mutant. (D) Potentiation of the γ-aminobutyric acid type A receptor (GABAAR) wild
type (WT) and F385A mutant by propofol, etomidate, isoflurane, alphaxalone, and trichloroethanol (TCEt). WT
values are shown in gray, whereas the mutant responses are shown in white. The bars represent the mean ±
SEM. *** Significance of P < 0.001.

Propofol Effects on the Single-channel Activity of the Propofol-hyposensitive GlyRs and
GABAARs

We next examined the effects of propofol on single-channel currents in wild type and mutant GlyR and GABAAR
using the outside-out configuration. For GlyRs, the results showed that both the wild type and F380A mutant
exhibited similar channel gating and conductance levels (fig. 6A–C) (table 1). Interestingly, the channel
conductance and open probability were not modified by the introduction of the F380 mutation. When propofol
(1 μM) was applied to a wild type GlyR, it produced a large enhancement in channel open probability (189 ± 36%
above control, n = 5) (fig. 6B). In agreement with the results obtained in whole cell recordings, the application of
propofol to membrane patches containing an F380A mutant channel did not increase channel activity (22 ± 13%
above control, n = 5, fig. 6B). Similar to GlyRs, the analysis of the GABAAR α1F385Aβ2mutant receptor showed
that conductance and open probability were not changed (table 1). However, the GABAAR α1β2wild type was
strongly enhanced by propofol (fig. 6D–F), whereas the GABAAR α1F385Aβ2mutant did not show any significant
potentiation (fig. 6E). Thus, these results demonstrate that mutations in intracellular sites did not cause
noticeable effects in either GlyR or GABAAR channel function, but specifically altered the sensitivity to propofol
of these receptors.

Fig. 6. Effects of propofol on single-channel function in wild type and mutated glycine receptor (GlyRs) and γaminobutyric acid type A receptor (GABAAR). (A) Single-channel activity recorded in wild type and F380A GlyRs
(calibration bar; 5 pA, 10 ms). (B) Percentage of the open probability (nPo) potentiation by propofol in the wild
type and F380A GlyRs. (C) Main conductance of the wild type and F380A GlyRs. (D) Single-channel activity
recorded in the wild type and F385A GABAAR (calibration bar; 2 pA, 10 ms). (E) Percentage of nPo potentiation in
the wild type and F385A GABAARs by propofol. (F) Main conductance of the wild type and F385A GABAAreceptor.
The bars represent the mean ± SEM. *** Significance of P < 0.001.

Table 1. Kinetics Parameters of Wild Type and Mutant GlyRs and GABAARs in Absence or Presence of Propofol
GlyRs
Glycine 1 µM
Condition MOT (ms)
MST (ms)
Wild type 1.15 ± 0.03
25.2 ± 4
F380A
1.35 ± 0.05
26.1 ± 3
GABAARs

Glycine 1 µM + Propofol 1 µM
Main γ (pS) nPo
MOT (ms)
MST (ms)
92 ± 3
0.048 1.07 ± 0.08
18.9 ± 4
90 ± 2
0.053 1.28 ± 0.05
22.7 ± 3

GABA 1 µM

Main γ (pS)
91 ± 3
90 ± 2

nPo
n
0.148 4
0.048 4

GABA 1 µM + Propofol 1 µM

Condition MOT (ms)

MST (ms)

Main γ (pS)

nPo

MOT (ms)

MST (ms)

19 Main γ

nPo

n

Wild type
F385A

18.3 ± 0.04
17.7 ± 0.03

19 ± 0.8
19 ± 0.6

0.25
0.31

1.14 ± 0.08
1.13 ± 0.05

17.9 ± 0.4
18.2 ±
0.03

(pS)± 0.5
20 ± 0.7

0.68
0.39

4
4

1.03 ± 0.03
1.18 ± 0.04

Discussion
In the current study, we provide evidence supporting a new role of the LIL for propofol actions in two members
of the Cys-loop superfamily. The data show that mutation of a phenylalanine residue, which is conserved in both
GABAAR and GlyRs, significantly reduced sensitivity to propofol. Single-channel recordings showed that kinetic
parameters of wild type and mutant receptors were very similar, suggesting that the reduction in propofol
sensitivity was not caused by changes in ion channel properties.
Previous studies showed that GABAAand GlyRs carrying mutations that affected the sensitivity to allosteric
modulators displayed altered gating properties.13,28,35,36 For instance, mutant GABAAand GlyRs with reduced
propofol, etomidate, and general anesthetic sensitivity showed significant changes in agonist potency and
channel gating.13,28,35,36 In addition, the mutant (S267Q in GlyRs)37 that showed reduced sensitivity to ethanol
and general anesthetics also displayed reduced channel gating activity.36 Thus, one can argue that the impaired
effects of several allosteric modulators in these mutant receptors were caused by changes in gating
mechanisms.13,28,35,–,37 In contrast, we found that mutation of F380 in α1GlyRs and F385 in α1GABAAsubunits
strongly reduced the allosteric modulation exerted by propofol without noticeable changes in the channel
properties. At the single-channel level, we found that low concentrations of glycine or GABA elicited singlechannel currents with conductances and mean open times similar to those previously published.37,38
In agreement with previous studies,39 we found that propofol increased the open probability, without changes in
mean open time, of GlyR and GABAARs. The absence of an effect of propofol on open time suggests that it does
not affect the channel closing rate. Thus, the increased open probability observed in this study is either
attributable to an increase in burst duration, which is in agreement with a study in GABAARs,40 or to an increase
in opening frequency. Further studies will be required to distinguish between these possibilities.
Our results suggest that the mutation of the conserved phenylalanine residue generates propofol-hyposensitive
GABAAand GlyRs through a mechanism that does not involve changes in ion channel gating. Therefore, our
results are consistent with the hypothesis that the impaired propofol sensitivity is caused by an alteration in
allosteric mechanisms rather than impaired ion channel function.
Regarding the subunits involved in propofol effects on GABAAR, previous reports have suggested that mutation
of residues in the β subunit were sufficient to abolish the sensitivity to propofol of αβ heteropentamers.17,34 In
contrast, our results showed that mutation of the F385 residue in the α1subunit strongly reduced the sensitivity
of GABAAR α1β2subunits to propofol. In agreement with our finding, it was demonstrated that GABAAR
containing the α6subunit were fourfold less sensitive to propofol than those with α1, independent of the
presence of β and γ subunits.41 Interestingly, sequence alignment of the LIL showed that although the α1subunit
has the phenylalanine residue, the α6subunit has an isoleucine residue in the homologous position. Thus, our
results are consistent with the hypothesis that the presence or absence of this phenylalanine residue within the
LIL influences propofol sensitivity.
Several studies have suggested that residues in TM regions of GABAARs and GlyRs can form a water-filled cavity
capable of binding propofol.15,–,20 In addition, these residues also influence the receptor sensitivity to several
structurally unrelated molecules.20,–,26 However, studies addressing the specificity of the residues involved in
anesthetic actions have yielded conflicting results. Although a single residue (Y444W) within the GABAAR
β2subunit was shown to be important for the action of propofol,14 a recent report showed that this mutation
also reduced potentiation by menthol,33 suggesting a lack of specificity. Furthermore, it was found that residues
in TM2 and TM3 of GlyRs and the homologous residues in the GABAAR reduced the sensitivity to alcohols and
volatile anesthetics without changes in the sensitivity to propofol.26 However, it was recently shown that the
same mutations affected the sensitivity to propofol.25 Our electrophysiological results, in contrast with both of

these studies, demonstrated that both GlyRs and GABAAR mutants conserved their sensitivity to other allosteric
modulators. For instance, the sensitivity to etomidate, previously suggested to share a binding site with propofol
in GABAARs,22,–,24 was not altered in the GABAAα1F385A mutant. Our findings suggest that the intracellular
phenylalanine residue is a determinant of propofol sensitivity in both GlyRs and GABAARs but does not appear to
affect the sensitivity to any other allosteric modulator.
Currently, high-resolution molecular features for the intracellular region connecting TM3 and TM4 in eukaryotic
Cys-loop ion channels are not available and only initial structural assessments can be obtained from homology
modeling. Previous studies in the 5-hydroxytryptamine3Areceptor have suggested that this region might be
structured as an α-helix (termed membrane-associated stretch).42,43 In agreement with this finding, a previous
model of α1GlyRs generated using the Torpedo nicotinic acetylcholine receptor as a template predicted an αhelical structure in this region.29,30 Even though our results can only suggest that the phenylalanine residue
forms a binding site, we speculate that propofol is accommodated by antiparallel helices and stabilized by
hydrophobic interactions with two phenylalanine residues nearby. This agrees with data obtained in crystallized
proteins in complex with propofol44,45 that showed that binding pockets are formed by the arrangement of two
helices, and that the putative cavity was lined by basic amino acids and hydrophobic residues, which provide the
necessary environment to accommodate the anesthetic molecule.
In conclusion, we have identified a conserved phenylalanine residue localized in the LIL, which influences the
propofol sensitivity of GlyRs and GABAARs. These results provide the first evidence indicating that the LIL plays a
role in anesthetic effects on inhibitory Cys-loop ion channels. Thus, these data provide new insights into the
molecular mechanism of modulation of inhibitory ion channels by propofol, and will contribute to the
understanding of the complex molecular framework underlying the modulation of central nervous system
activity by general anesthetics.
The authors thank Lauren Aguayo, B.S. (Technician, Department of Physiology, Faculty of Biological Sciences,
University of Concepción, Concepción, Chile), for technical assistance and help with the GlyR constructions.
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